Fig. 6From: Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi ArabiaBootstrap Distribution of Cost-Effectiveness: Risankizumab vs. Adalimumab, Assuming Weekly Dosing, Cheapest Biosimilar for Adalimumab, and a 40% Public Price Reduction for RisankizumabBack to article page